Trial Profile
A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms STAH
- 05 Dec 2018 Results published in the Journal of Hepatology
- 14 Apr 2018 Results presented at The International Liver Congress 2018
- 27 Mar 2018 Status changed from active, no longer recruiting to completed.